Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PARI GmbH
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
Five new OTC cough and cold products have hit the shelves in Germany this winter from Pari, Pohl Boskamp, Engelhard Arzneimittel, GSK and Dr Soldan.
- Medical Devices
- Drug Delivery
- Site Specific
- Other Names / Subsidiaries
- PARI Medical Holding
- PARI Pharma GmbH
- PARltec GmbH
- PARI Worldwide, PARI Respiratory Equipment, Inc.